Pedro A. De Alarcon
Expertise in
8
conditions

Dr. Pedro A. De Alarcon

Pediatrics
530 Northeast Glen Oak Avenue, 
Peoria, IL 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
8
conditions
530 Northeast Glen Oak Avenue, 
Peoria, IL 

Overview

Pedro De Alarcon is a Pediatrics provider practicing medicine in Peoria, Illinois.

Dr. De Alarcon is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Hepatoblastoma, and Bone Marrow Aspiration.

Dr. De Alarcon is board certified in American Board Of Pediatrics. He is actively involved in clinical research, co-authoring 36 peer reviewed articles and participating in 49 clinical trials.

Graduate Institution

The George Washington University, 1972

Residency

University of Vermont Medical Center, Pediatrics, 1976

Specialties

Pediatrics

Licenses

Pediatric Hematology-Oncology in TN

Board Certifications

American Board Of Pediatrics

Fellowships

St. University of New York, Pediatric Hematology-Oncology, 1979

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

OSF Children's Hospital of Illinois - Pediatric Cancer and Blood Clinic
530 Northeast Glen Oak Avenue, Peoria, IL 61637

Additional Areas of Focus

Dr. De Alarcon has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

49 Clinical Trials

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: April 07, 2026
Intervention Type: Procedure, Biological, Drug, Other
Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate
Study Phase: Phase 3
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Enrollment Status: Active_not_recruiting
Publish Date: April 14, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Ensartinib, Erdafitinib, Larotrectinib, Olaparib, Palbociclib, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib
Study Phase: Phase 2
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Doxorubicin, Ifosfamide, Pazopanib
Study Phase: Phase 2/Phase 3
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Ganitumab, Ifosfamide, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Other, Drug
Study Drug: Ensartinib
Study Phase: Phase 2
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Other
Study Drugs: Cabozantinib, Cabozantinib-S-Malate
Study Phase: Phase 2
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Cyclophosphamide, Doxorubicin, Etoposide, Methylprednisolone, Prednisone, Vincristine
Study Phase: Phase 3
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
Enrollment Status: Active_not_recruiting
Publish Date: April 07, 2026
Intervention Type: Other, Drug
Study Drug: Ulixertinib
Study Phase: Phase 2
Umbrella Long-Term Follow-Up Protocol
Umbrella Long-Term Follow-Up Protocol
Enrollment Status: Active_not_recruiting
Publish Date: April 06, 2026
Intervention Type: Procedure, Other
View 9 Less Clinical Trials

36 Total Publications

Impact of the Supreme Court and State Legislation on Pediatric Diversity Initiatives.
Impact of the Supreme Court and State Legislation on Pediatric Diversity Initiatives.
Journal: The Journal of pediatrics
Published: August 10, 2025
Similar Doctors
Expertise in
22
conditions
Dr. Matthew J. Gorman
Pediatrics | Internal Medicine
Expertise in
22
conditions
Dr. Matthew J. Gorman
Pediatrics | Internal Medicine

OSF Medical Group - Primary Care

10 Saint Clare Court Suite 100, 
Washington, IL 
 (9.0 miles away)
309-886-4000
Languages Spoken:
English
See accepted insurances

Matthew Gorman is a primary care provider, practicing in Pediatrics and Internal Medicine in Washington, Illinois. Dr. Gorman is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Otitis, Parainfluenza Virus Type 3, Parainfluenza, and Cellulitis. Dr. Gorman is board certified in Medical Education and Residency, Internal Medicine.

Expertise in
14
conditions
Dr. Marc D. Knepp
Cardiology | Pediatrics | Pediatric Cardiology
Expertise in
14
conditions
Dr. Marc D. Knepp
Cardiology | Pediatrics | Pediatric Cardiology

OSF Children's Hospital Of Illinois - Congenital Heart Center

420 Northeast Glen Oak Avenue Suite 301, 
Peoria, IL 
 (1.0 miles away)
800-443-9898
Languages Spoken:
English
See accepted insurances

Marc Knepp is an Internal Medicine specialist and a Pediatrics provider practicing medicine in Peoria, Illinois. Dr. Knepp is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Atrioventricular Septal Defect, Partial Atrioventricular Canal, Endocardial Cushion Defect, and Isthmian Coarctation. Dr. Knepp is board certified in American Board Of Internal Medicine and American Board Of Pediatrics.

Expertise in
1
conditions
Dr. Amy L. Christison
Bariatric Medicine | Pediatrics
Expertise in
1
conditions
Dr. Amy L. Christison
Bariatric Medicine | Pediatrics

OSF Children's Hospital Of Illinois - Healthy Kids U

420 Northeast Glen Oak Avenue Suite 201, 
Peoria, IL 
 (1.0 miles away)
309-624-9844
Languages Spoken:
English
See accepted insurances

Amy Christison is a Pediatrics specialist and a Bariatric Medicine provider practicing medicine in Peoria, Illinois. Dr. Christison is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Obesity in Children. Dr. Christison is board certified in American Board Of Obesity Medicine and American Board Of Pediatrics.

Frequently Asked Questions about Dr. Pedro A. De Alarcon

How do I make an appointment with Dr. Pedro A. De Alarcon?

You can book an appointment with Dr. Pedro A. De Alarcon by calling their office at 309-624-4945. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Pedro A. De Alarcon a top-rated expert for Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Pedro A. De Alarcon is classified as an Distinguished expert for Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Pedro A. De Alarcon specialize in?

While Dr. Pedro A. De Alarcon is a Pediatrics, they have specific expertise in Hodgkin Lymphoma, Neuroblastoma, and Embryonal Tumor with Multilayered Rosettes. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatrics.

Does Dr. Pedro A. De Alarcon participate in research or clinical trials?

Yes. Dr. Pedro A. De Alarcon has published 36 articles and abstracts on conditions like Hodgkin Lymphoma. You can view a list of Dr. Pedro A. De Alarcon's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Pedro A. De Alarcon accept my insurance?

Dr. Pedro A. De Alarcon accepts most major insurance plans, including Humana. We recommend calling the office directly at 309-624-4945 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. De Alarcon's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 16 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile